Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy.

cholangiocarcinoma hepatocellular carcinoma liver metastases neoadjuvant therapy transplantation

Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 24 11 2018
accepted: 26 11 2018
entrez: 24 1 2019
pubmed: 24 1 2019
medline: 27 1 2019
Statut: ppublish

Résumé

Liver transplantation is a surgical option with curative intent used in the management of some cases of hepatocellular carcinoma and cholangiocarcinoma (hilar, rarely intrahepatic). A number of different therapeutic modalities including ablative techniques, arterially directed therapies, radiation and chemotherapy are used in the neoadjuvant setting prior to liver transplantation with the goals of preventing tumour progression, decreasing post-transplant recurrence and possibly downstaging patients with tumour burden beyond what is acceptable by current transplant criteria. Pathologists evaluating hepatic explants must be aware of these neoadjuvant therapies and the alterations induced by them in both tumourous and non-tumourous tissue. In this review, we discuss common neoadjuvant therapies used in in this setting, as well as the gross and microscopic changes induced by these presurgical treatments within hepatic neoplasms as well as the background hepatic parenchyma and nearby structures. Select secondary tumours involving the liver which are pretreated will also be discussed. Finally, proper reporting of these changes will be mentioned.

Identifiants

pubmed: 30670563
pii: jclinpath-2018-205596
doi: 10.1136/jclinpath-2018-205596
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-119

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Anjelica Hodgson (A)

Department of Pathobiology and Laboratory Medicine, The University of Toronto, Toronto, Ontario, Canada.
Department of Pathology, University Health Network, Toronto, Ontario, Canada.

Zuhoor Almansouri (Z)

Department of Pathobiology and Laboratory Medicine, The University of Toronto, Toronto, Ontario, Canada.
Department of Pathology, University Health Network, Toronto, Ontario, Canada.

Oyedele Adeyi (O)

Department of Pathobiology and Laboratory Medicine, The University of Toronto, Toronto, Ontario, Canada.
Department of Pathology, University Health Network, Toronto, Ontario, Canada.

Sandra E Fischer (SE)

Department of Pathobiology and Laboratory Medicine, The University of Toronto, Toronto, Ontario, Canada dr.sandra.fischer@uhn.ca.
Department of Pathology, University Health Network, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH